Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2452609 | 1.00 | ADRB2 (0.38) | ADRB2ADRB1ADRB3CYP19A1CYP11B1 | |
| SCHEMBL2452051 | 0.86 | LIPG (0.38) | ADRB2ADRB1ADRB3CYP19A1TBXAS1 | |
| SCHEMBL2452050 | 0.86 | LIPG (0.38) | ADRB2ADRB1ADRB3CYP19A1TBXAS1 | |
| SCHEMBL2449881 | 0.85 | ALDH1A1 (0.40) | ADRB2ADRB1ADRB3KDM4EALDH1A1 | |
| SCHEMBL2449877 | 0.85 | ALDH1A1 (0.40) | ADRB2ADRB1ADRB3KDM4EALDH1A1 | |
| SCHEMBL2453666 | 0.83 | ADRB2 (0.39) | ADRB2ADRB1ADRB3CYP19A1CYP11B1 | |
| SCHEMBL2449461 | 0.83 | ADRB2 (0.35) | ADRB2ADRB1ADRB3CYP19A1CYP11B1 | |
| SCHEMBL2449454 | 0.83 | ADRB2 (0.35) | ADRB2ADRB1ADRB3CYP19A1CYP11B1 | |
| SCHEMBL2453671 | 0.83 | ADRB2 (0.39) | ADRB2ADRB1ADRB3CYP19A1CYP11B1 | |
| SCHEMBL2452897 | 0.82 | IDO1 (0.43) | ADRB2ADRB1ADRB3CYP19A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022072-B2 | Azolylmethylidenehydrazine derivative and use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | claimed |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-29 | — | — | US | claimed |
| EP-2168951-A1 | AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-31 | — | — | EP | claimed |
| US-8022072-B2 | Azolylmethylidenehydrazine derivative and use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2168951-A1 | AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | ARSA, AHR, HRH2 | ADRB2 16/4885ADRB1 33/4885ADRB3 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.